Antithrombotic Drug Therapy in Cardiovascular Disease / edited by Arman T. Askari, A. Michael Lincoff
Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Written by experts in the field, "Antithrombotic Drug Therapy in Cardiovascular Disease" carefully examines individual and various combination.
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
New York: Humana Press ; 2010 |
| Reproduktion: |
Online-Ausg. ; Springer eBook Collection. Medicine |
|---|---|
| Weitere Ausgaben: |
Druckausg.: Antithrombotic drug therapy in cardiovascular disease |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Askari, Arman T. [Sonstige Person] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| ISBN: |
|---|
| RVK: |
|---|
| Anmerkungen: |
Includes bibliographical references and index |
|---|
| Umfang: |
Online-Ressource ; v.: digital |
|---|
| doi: |
10.1007/978-1-60327-235-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
632389923 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 632389923 | ||
| 003 | DE-627 | ||
| 005 | 20230427103820.0 | ||
| 007 | cr ||||||||||| | ||
| 008 | 100809s2010 ne |||||o 00| ||eng c | ||
| 020 | |a 9781603272353 |9 978-1-60327-235-3 | ||
| 024 | 7 | |a 10.1007/978-1-60327-235-3 |2 doi | |
| 035 | |a (DE-627)632389923 | ||
| 035 | |a (DE-599)BVBBV036123788 | ||
| 035 | |a (OCoLC)699652392 | ||
| 035 | |a (DE-He213)978-1-60327-235-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 044 | |c XA-NL | ||
| 050 | 0 | |a RC671.5 | |
| 060 | 0 | |a WG 300 | |
| 082 | 0 | |a 615.718 | |
| 084 | |a XI 4300 |q BVB |2 rvk |0 (DE-625)rvk/153005:12905 | ||
| 084 | |a YB 8700 |q BVB |2 rvk |0 (DE-625)rvk/153168:12905 | ||
| 084 | |a 44.85 |2 bkl | ||
| 245 | 1 | 0 | |a Antithrombotic Drug Therapy in Cardiovascular Disease |c edited by Arman T. Askari, A. Michael Lincoff |
| 264 | 1 | |a New York |b Humana Press |c 2010 | |
| 300 | |a Online-Ressource |b v.: digital | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a Contemporary Cardiology | |
| 500 | |a Includes bibliographical references and index | ||
| 505 | 8 | 0 | |a Anchor 2; Askari_Ch01_O.pdf; 1; Platelets in Arterial Thrombosis; PLATELETS IN THROMBUS FORMATION; PLATELET ADHESION AND ITS RECEPTORS; Platelet-Collagen Interactions; GPIb-IX-V; GPVI; Integrin a2b1; Other Adhesion Receptors; AGONIST RECEPTORS; ADP Receptors; P2Y1 Receptors; P2Y12 Receptors; P2X1 Receptors; PROTEASE-ACTIVATED RECEPTORS; THROMBOXANE A2 RECEPTORS; PLATELET AGGREGATION AND ITS RECEPTORS; aIIbb3; Modulators of Platelet Aggregation; REFERENCES; Askari_Ch02_O.pdf; 2; The Role of Coagulation in Arterialand Venous Thrombosis; INTRODUCTION |
| 505 | 8 | 0 | |a CLINICAL MANIFESTATIONS OF ARTERIAL AND VENOUS THROMBOSISCOAGULATION PHYSIOLOGY; The Intrinsic Pathway; The Extrinsic Pathway; Fibrin Formation and Common Pathway Activation; Lessons from Studying In Vivo Coagulation Activation; REGULATION OF COAGULATION; Regulation of Tissue Factor; Regulation of Thrombin; Protein Z System; Role of Endothelium; Role of Microparticles; Interaction Between Coagulation and Platelet Activation; COAGULATION DYSREGULATION IN ARTERIAL AND VENOUS THROMBOSIS; Coagulation Dysregulation and Venous Thromboembolic Disease; Congenital Thrombophilia; Factor V Leiden |
| 505 | 8 | 0 | |a Prothrombin G20210AAcquired Thrombophilia; The Role of Coagulation in Arterial Disease; Links Between Coagulation and Atherosclerosis; Role of Thrombophilia Risk Factors in Arterial Thrombosis; SUMMARY; References; Askari_Ch03_O.pdf; 3; The Link Between Inflammation and Thrombosis; PATHOBIOLOGY OF INFLAMMATION, ATHEROSCLEROSIS, AND ACS; Endothelial Function; Adhesion Molecules; Cellular and Humoral-Mediated Response; Monocytes and Macrophages; Mast Cells; Neutrophils; Platelets; Chemokines and Cytokines; Chemokines; Tumor Necrosis Factor-a; Interleukins; CD40 and CD4OL |
| 505 | 8 | 0 | |a Nuclear Transcription FactorsNF-kB; PPAR; Other Mediators; Myeloperoxidase; A2 Phospholipases; Angiogenic Growth Factors; MARKERS AND MEDIATORS OF INFLAMMATION; C-Reactive Protein and Serum Amyloid A; THE FUTURE OF INFLAMMATION CONTROL IN ACS; Aspirin; HMG-CoA Reductase Inhibitors (Statins); ACE Inhibitors; Thrombin Receptor Antagonists; Inhibition of Cell-to-Cell Interaction; CLOSING THOUGHTS AND CAUTIONARY ACCOUNTS FROM PREVIOUS ANTI-INFLAMMATORY STRATEGIES; REFERENCES; Askari_Ch04_O.pdf; 4; The Genetics of Thrombosis; INTRODUCTION; Evidence For a Genetic Basis To Thrombosis |
| 505 | 8 | 0 | |a The Evolutionary Basis of CoagulationTHE GENETICS OF COAGULATION AND THROMBOSIS IN HUMANS; Linkage Analysis To Define Genetics Of Thrombosis; Association Studies In Genetics Of Thrombosis; GENETIC VARIANTS IMPLICATED IN VENOUS THROMBOTIC DISORDERS; Antithrombin III Deficiency; Protein S Deficiency; Protein C Deficiency; Activated Protein C Resistance (Factor V Leiden); Other Forms of Activated Protein C Deficiencies; Prothrombin 20210A; Hyperhomocysteinemia; Lupus Anticoagulant/Antiphospholipid Antibodies; Other Genetic Factors Associated with VTE |
| 505 | 8 | 0 | |a Laboratory Assays and Diagnostic Testing for Hereditary VTE |
| 520 | |a Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Written by experts in the field, "Antithrombotic Drug Therapy in Cardiovascular Disease" carefully examines individual and various combination | ||
| 530 | |a Electronic reproduction; Available via World Wide Web | ||
| 533 | |a Online-Ausg. |f Springer eBook Collection. Medicine |n Electronic reproduction; Available via World Wide Web | ||
| 650 | 0 | |a Medicine | |
| 650 | 0 | |a Interventional radiology | |
| 650 | 0 | |a Internal medicine | |
| 650 | 0 | |a Cardiology | |
| 650 | 0 | |a Vascular Surgery | |
| 650 | 2 | |a Cardiovascular Diseases |x drug therapy | |
| 650 | 2 | |a Fibrinolytic Agents |x therapeutic use | |
| 650 | 2 | |a Thrombolytic Therapy |x methods | |
| 689 | 0 | 0 | |D s |0 (DE-588)4024666-8 |0 (DE-627)104806338 |0 (DE-576)208956743 |a Kardiovaskuläre Krankheit |2 gnd |
| 689 | 0 | 1 | |D s |0 (DE-588)4124936-7 |0 (DE-627)105743925 |0 (DE-576)209572329 |a Antithrombotikum |2 gnd |
| 689 | 0 | |5 (DE-627) | |
| 700 | 1 | |a Askari, Arman T. |4 oth | |
| 700 | 1 | |a Lincoff, A. Michael |4 oth | |
| 776 | 1 | |z 9781603272346 | |
| 776 | 0 | 8 | |i Druckausg. |t Antithrombotic drug therapy in cardiovascular disease |d New York, NY : Humana Press [u.a.], 2010 |h XIII, 475 S. |w (DE-627)573350574 |z 9781603272346 |z 1603272348 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-1-60327-235-3 |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 2 | |u http://www.gbv.de/dms/bowker/toc/9781603272346.pdf |m V:DE-601 |m X:Bowker |q pdf/application |v 2011-12-23 |x Verlag |y Inhaltsverzeichnis |3 Inhaltsverzeichnis |
| 912 | |a ZDB-2-SME |b 2010 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a ISIL_DE-3 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a ISIL_DE-Ma9 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a ISIL_DE-Ma14 | ||
| 936 | r | v | |a XI 4300 |b Allgemeines |k Medizin |k Pharmakologie und Toxikologie |k Spezielle Pharmakologie und Toxikologie |k Kardiovaskuläres System: Herzmittel, Digitalisglykoside, Strophantine, Coffein, zentrale Analeptika |k Allgemeines |0 (DE-627)1271501619 |0 (DE-625)rvk/153005:12905 |0 (DE-576)201501619 |
| 936 | r | v | |a YB 8700 |b Allgemeines |k Medizin |k Innere Medizin |k Spezielle Innere Medizin |k Brustorgane |k Kardiovaskuläres System |k Allgemeines über Herz und Kreislauf |k Allgemeine Therapie |k Allgemeine Therapie |k Allgemeines |0 (DE-627)1271603071 |0 (DE-625)rvk/153168:12905 |0 (DE-576)201603071 |
| 936 | b | k | |a 44.85 |j Kardiologie |j Angiologie |0 (DE-627)106409417 |
| 951 | |a BO | ||
| 953 | |2 045F |a 615.718 | ||
| 980 | |2 22 |1 01 |x 0018 |b 1217654917 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |h OLR-SEB |k Campuslizenz Universität Hamburg. - Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y zi06404 |z 09-01-11 | ||
| 980 | |2 65 |1 01 |x 0003/5555 |b 4305083671 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |c 03 |f --%%-- |d ebook |e --%%-- |j --%%-- |h OLR-SEB-ZDB-2-SME |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Die Weitergabe an Dritte sowie systematisches Downloaden sind untersagt. |y k3o |z 07-04-23 | ||
| 980 | |2 74 |1 01 |x 0354 |b 1286495253 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |c 09 |f E-Bibl |d EK 0043 |e --%%-- |j --%%-- |h OLR-ESP |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden. |y ze |z 28-08-12 | ||
| 980 | |2 100 |1 01 |x 3100 |b 1176175394 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |c 09 |f --%%-- |d eBook Springer |e --%%-- |j --%%-- |h OLR-SEB |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y z |z 12-08-10 | ||
| 980 | |2 101 |1 01 |x 3101 |b 1176190156 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |c 09 |f --%%-- |d eBook Springer |e --%%-- |j --%%-- |h OLR-SEB |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y z |z 12-08-10 | ||
| 981 | |2 22 |1 01 |x 0018 |y Volltextzugang |r http://dx.doi.org/10.1007/978-1-60327-235-3 | ||
| 981 | |2 22 |1 01 |x 0018 |y Nur für Angehörige der Universität Hamburg: Volltextzugang von außerhalb des Campus |r http://emedien.sub.uni-hamburg.de/han/SpringerEbooksUKE/dx.doi.org/10.1007/978-1-60327-235-3 | ||
| 981 | |2 65 |1 01 |x 0003/5555 |y Volltextzugang Campus |r http://dx.doi.org/10.1007/978-1-60327-235-3 | ||
| 981 | |2 74 |1 01 |x 0354 |y Volltext, Campuszugriff |r http://dx.doi.org/10.1007/978-1-60327-235-3 | ||
| 981 | |2 74 |1 01 |x 0354 |y Volltext, Externer Zugriff |r http://mhh.hh-han.com/han/springer-ebook/dx.doi.org/10.1007/978-1-60327-235-3 | ||
| 981 | |2 100 |1 01 |x 3100 |r http://dx.doi.org/10.1007/978-1-60327-235-3 | ||
| 981 | |2 100 |1 01 |x 3100 |y für Uniangehörige: Zugang weltweit |r https://han.med.uni-magdeburg.de/han/SPR-eBook-Medicine-einzeln/dx.doi.org/10.1007/978-1-60327-235-3 | ||
| 981 | |2 101 |1 01 |x 3101 |r http://www.springerlink.com/content/978-1-60327-234-6 | ||
| 981 | |2 101 |1 01 |x 3101 |y für Uniangehörige: Zugang weltweit |r https://han.med.uni-magdeburg.de/han/SPR-eBook-Medicine-einzeln/www.springerlink.com/content/978-1-60327-234-6 | ||
| 981 | |2 101 |1 01 |x 3101 |r http://dx.doi.org/10.1007/978-1-60327-235-3 | ||
| 981 | |2 101 |1 01 |x 3101 |y für Uniangehörige: Zugang weltweit |r https://han.med.uni-magdeburg.de/han/SPR-eBook-Medicine-einzeln/dx.doi.org/10.1007/978-1-60327-235-3 | ||
| 982 | |2 74 |1 00 |x DE-354 |8 00 |a Cardiovascular Diseases-drug therapy | ||
| 982 | |2 74 |1 00 |x DE-354 |8 01 |a Fibrinolytic Agents-therapeutic use | ||
| 982 | |2 74 |1 00 |x DE-354 |8 02 |a Thrombolytic Therapy-methods | ||
| 983 | |2 74 |1 00 |x DE-354 |8 00 |a WG 300 | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EK 0043 | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 2109 | ||
| 995 | |2 22 |1 01 |x 0018 |a OLR-SEB | ||
| 995 | |2 65 |1 01 |x 0003/5555 |a OLR-SEB-ZDB-2-SME | ||
| 995 | |2 74 |1 01 |x 0354 |a OLR-ESP | ||
| 995 | |2 74 |1 01 |x 0354 |a ACQ | ||
| 995 | |2 100 |1 01 |x 3100 |a OLR-SEB | ||
| 995 | |2 101 |1 01 |x 3101 |a OLR-SEB | ||